Cholesterol Drug Showing Promise Against COVID-19 Fails in Human Trials; Unable to Reduce Severe Symptoms or Death in Patients: Study

A new international multi-institutional study led by scientists from Penn Medicine has found that fenofibrate was unable to reduce the severity of disease or prevent adverse outcomes such as deaths in COVID-19 patients.

Related Keywords

United States ,America ,Pexelx Pavel Danilyuk ,Wikimedia Commons ,Julio Chirinos ,Jordanab Cohen ,National Institute For Health ,Drug Administration ,Penn Medicine ,Fighting Fat ,Representational Picture ,National Institute ,Care Excellence ,Western Asia ,North America ,Cholesterol Drugs Covid 19 ,Cholesterol Drugs Fails Covid 19 Human Trials ,Fenofibrate Fails To Prevent Severe Covid 19 Outcomes ,Cholesterol Drug Fails To Prevent Severe Covid 19 Outcomes ,Cholesterol Drugs Covid 19 Fails In Human Trials ,New Covid 19 Discovery ,New Covid 19 Study ,Cholesterol Drug Fenofibrate Covid 19 ,Cholesterol Drug Fenofibrate Covid 19 Fails To Reduce Death ,Cholesterol Drug Fenofibrate Covid 19 Fails Disease Severity ,Health News ,Trending Health News ,